Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorBasas Satorras, Jana
dc.contributor.authorPalau Gauthier, Marta
dc.contributor.authorGomis Rodriguez, Javier
dc.contributor.authorAlmirante Gragera, Benito
dc.contributor.authorGavaldà Santapau, Joan
dc.date.accessioned2019-03-07T11:13:50Z
dc.date.available2019-03-07T11:13:50Z
dc.date.issued2019-02-19
dc.identifier.citationBasas J, Palau M, Gomis X, Almirante B, Gavaldà J. Efficacy of liposomal amphotericin B and anidulafungin using an antifungal lock technique (ALT) for catheter-related Candida albicans and Candida glabrata infections in an experimental model. PLoS One. 2019;14(2):e0212426.
dc.identifier.issn1932-6203
dc.identifier.urihttp://hdl.handle.net/11351/3837
dc.descriptionLiposomal amphotericin B; Antifungal lock technique; Candida albicans
dc.description.abstractOBJECTIVE: The aims of this study were as follows. First, we sought to compare the in vitro susceptibility of liposomal amphotericin B (LAmB) and anidulafungin on Candida albicans and Candida glabrata biofilms growing on silicone discs. Second, we sought to compare the activity of LAmB versus anidulafungin for the treatment of experimental catheter-related C. albicans and C. glabrata infections with the antifungal lock technique in a rabbit model. METHODS: Two C. albicans and two C. glabrata clinical strains were used. The minimum biofilm eradication concentration for 90% eradication (MBEC90) values were determined after 48h of treatment with LAmB and anidulafungin. Confocal microscopy was used to visualize the morphology and viability of yeasts growing in biofilms. Central venous catheters were inserted into New Zealand rabbits, which were inoculated of each strain of C. albicans and C. glabrata. Then, catheters were treated for 48h with saline or with antifungal lock technique using either LAmB (5mg/mL) or anidulafungin (3.33mg/mL). RESULTS: In vitro: anidulafungin showed greater activity than LAmB against C. albicans and C. glabrata strains. For C. albicans: MBEC90 of anidulafungin versus LAmB: CA176, 0.03 vs. 128 mg/L; CA180, 0.5 vs. 64 mg/L. For C. glabrata: MBEC90 of anidulafungin versus LAmB: CG171, 0.5 vs. 64 mg/L; CG334, 2 vs. 32 mg/L. In vivo: for C. albicans species, LAmB and anidulafungin achieved significant reductions relative to growth control of log10 cfu recovered from the catheter tips (CA176: 3.6±0.3 log10 CFU, p≤0.0001; CA180: 3.8±0.1 log10 CFU, p≤0.01). For C. glabrata, anidulafungin lock therapy achieved significant reductions relative to the other treatments (CG171: 4.8 log10 CFU, p≤0.0001; CG334: 5.1 log10 CFU, p≤0.0001). CONCLUSIONS: For the C. albicans strains, both LAmB and anidulafungin may be promising antifungal lock technique for long-term catheter-related infections; however, anidulafungin showed significantly higher activity than LAmB against the C. glabrata strains.
dc.language.isoeng
dc.publisherPublic Library of Science
dc.relation.ispartofseriesPLoS ONE;14(2)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectAmfotericina B
dc.subjectCandidiasi
dc.subjectCandida albicans
dc.subject.meshAmphotericin B
dc.subject.mesh/therapeutic use
dc.subject.meshCandidiasis
dc.subject.mesh/immunology
dc.titleEfficacy of liposomal amphotericin B and anidulafungin using an antifungal lock technique (ALT) for catheter-related Candida albicans and Candida glabrata infections in an experimental model
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1371/journal.pone.0212426
dc.subject.decsanfotericina B
dc.subject.decs/uso terapéutico
dc.subject.decscandidiasis
dc.subject.decs/inmunología
dc.relation.publishversionhttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0212426
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliationDepartament de malalties infeccioses, Vall d’Hebron Institut de Recerca, Barcelona, Spain. Servei de pneumologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain
dc.identifier.pmid30779771
dc.identifier.wosWOS:000459062900054
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record